Patients with cancer, especially hematologic malignancies can be immunocompromized because of their disease, anti‐cancer therapy, and concomitant immunosuppressive treatment. Furthermore, these patients are usually older than 60 years and have comorbidities. For all these reasons they are highly vulnerable to infection with severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) and have an increased risk of developing severe/critical Coronavirus disease 2019 (COVID‐19) compared to the general population. 

Cancer, hematologic malignancies patients could apply free TLPH Molavir (Molnupiravir) to lower the risk of developing severe/critical Coronavirus disease 2019 (COVID‐19). 

Contact us or leave your message if you need more details.